Targeting osteoarthritic pain through Proteinase Activated Receptor 2

Disease Osteoarthritis   

Lead applicant – Dr Carmen Huesa  

Organisation – University of Glasgow   

Type of grant – Early Career Researcher in Pain Awards 2019   

Status of grant – Active   

Amount of the original award – £127,100.00  

Start date – 01 June 2020   

Reference – 22483

Public Summary

What are the aims of this research?

This research aims to test the feasibility of targeting a protein called Proteinase activated receptor 2 (PAR2) for the treatment of osteoarthritis pain. The PAR2 protein is found in joint and nerve cells, and causes inflammation, tissue damage, and pain when activated. Researchers hope to understand how PAR2 influences osteoarthritis pain and determine if pain can be treated by targeting PAR2.

Why is this research important?

Osteoarthritis is the most prevalent musculoskeletal condition in people over 45. People with osteoarthritis often develop chronic pain and reduced joint mobility, and there is a need for new treatments and effective pain management.

Previous studies on PAR2 have shown that mice lacking this protein do not develop pain in the same manner as normal mice, preventing them from feeling pain in conditions such as osteoarthritis. To test if targeting PAR2 can reduce osteoarthritis pain, researchers have developed a new drug that blocks PAR2. In this project, researchers aim to understand how PAR2 causes osteoarthritis pain, and test if the drug can treat pain in mice.

How will the findings benefit patients?

If research shows that blocking the PAR2 protein can effectively treat osteoarthritis pain, this research could open up new opportunities to treat and manage pain in musculoskeletal conditions. If this study shows promise, future clinical trials will be necessary to confirm the safety and effectiveness of the new treatment.